CompletedNCT03993535
Predicting Treatment Response in OCD
About this title
Read the official source —Medication studyAges 18–50Multiple countries
Understand this study
Who was this study for?
This study was for people with OCD. Listed age limits: 18 years to 50 years. Other eligibility criteria applied.
- Listed locations
- New York and 3 more locationsSee all locations and recruitment
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Study information
Study start dateStarted: October 10, 2018
- Recruitment status
- Completed
- Enrollment listed in the registry
- 250
- Sponsor
- University of Sao Paulo
- Sponsor type
- University
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- United States, Brazil, India, ...
- Age range
- From 18 Years to 50 Years
- Official registry ID
- NCT03993535
- Official title
Show the full official title
Clinical, Neurocognitive and Neuroimaging Variables Associated With Response to Treatment in Patients With OCD
Get this study by email
Recruitment & locations
CompletedNew York, United States · São Paulo, Brazil · Bangalore, India
1 more locations
- Cape Town, South Africa
Questions about this study
Who is behind this study?
The study sponsor is University of Sao Paulo, a university.
Did this study involve medication?
Yes. The study involved medication, including selective serotonin reuptake inhibitor.
Who was this study for?
This study was for people with OCD. Listed age limits: 18 years to 50 years. Other eligibility criteria applied.
